Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

New England Journal of Medicine

Volumn 353, Issue 20, 2005, Pages 2121-2134

  Després, Jean Pierre ^a,b   Golay, Alain ^c   Sjöström, Lars ^d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; AGGRESSION; AMNESIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BENIGN TUMOR; BODY MASS; BODY WEIGHT; BREAST DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; DYSPEPSIA; EYE DISEASE; FATIGUE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INFLUENZA; INJURY; INSOMNIA; IRRITABILITY; KIDNEY DISEASE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; OBESITY; PNEUMONIA; POLYP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; VASCULAR DISEASE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RISK FACTORS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 27844463517     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa044537     Document Type: Article

References (38)

1. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50.
2. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.
3. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.
4. Horvath TL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 2003;112:323-6.
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
6. Hanus L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001;98:3662-5.
7. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
8. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5.
9. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-7.
10. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005;365:1363-4.
11. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
12. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-9.
13. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-14.
14. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
15. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
17. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001;104:2295-9.
18. Laboratory test handbook. 4th ed. Hudson (Cleveland): Lexi-Comp, 1996.
19. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
20. Després JP. Drug treatment for obesity: we need more studies in men at higher risk of coronary events. BMJ 2001;322:1379-80.
21. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: a randomized, controlled trial. Ann Intern Med 2000;133:92-103.
22. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10:497-511.
23. Tchernof A, Lamarche B, Prud'homme D, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.
24. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
25. Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis 2000;148:151-8.
26. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 2001;87:2B-7B.
27. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
28. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
29. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
30. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
31. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-70.
32. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-3.
33. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
34. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 1997;46:1594-600.
35. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura KK, Matsuzawa Y. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27:125-9.
36. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
37. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-8. [Erratum, Lancet 2002;361:1060.]
38. Côté M, Mauriège P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005;90:1434-9.